Inhibitory effects of calcium channel blockers nisoldipine and nimodipine on ivacaftor metabolism and their underlying mechanism

• Main Authors: Hailun Xia (Author), Xinhao Xu (Author), Jie Chen (Author), Hualu Wu (Author), Yuxin Shen (Author), Xiaohai Chen (Author), Ren-ai Xu (Author), Wenzhi Wu (Author)
• Format: Book
• Published: Frontiers Media S.A., 2024-09-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Ivacaftor is the first potentiator of the cystic fibrosis transmembrane conductance regulator (CFTR) protein approved for use alone in the treatment of cystic fibrosis (CF). Ivacaftor is primarily metabolized by CYP3A4 and therefore may interact with drugs that are CYP3A4 substrates, resulting in ch...